A multicenter phase II study in adults with untreated acute lymphoblastic leukemia: testing pharmacokinetically individualized doses of L-asparaginase following the DFCI Pediatric Consortium protocol.

Trial Profile

A multicenter phase II study in adults with untreated acute lymphoblastic leukemia: testing pharmacokinetically individualized doses of L-asparaginase following the DFCI Pediatric Consortium protocol.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Oct 2017

At a glance

  • Drugs Asparaginase (Primary) ; Cytarabine; Dexamethasone; Doxorubicin; Folinic acid; Folinic acid; Hydrocortisone; Mercaptopurine; Methotrexate; Methotrexate; Prednisone; Vincristine
  • Indications Acute lymphoblastic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 15 Jun 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 15 Jun 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
    • 11 Feb 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top